<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993031</url>
  </required_header>
  <id_info>
    <org_study_id>H5741-34342</org_study_id>
    <secondary_id>P01HD059454</secondary_id>
    <secondary_id>2009-141</secondary_id>
    <secondary_id>HS-670</secondary_id>
    <secondary_id>592/ESR/NDA/DID-09/2009</secondary_id>
    <secondary_id>H5741-34342 and 10-02958</secondary_id>
    <nct_id>NCT00993031</nct_id>
  </id_info>
  <brief_title>Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women</brief_title>
  <acronym>PROMOTE-PIs</acronym>
  <official_title>Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single site, randomized controlled trial comparing protease
      inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected
      pregnant and breastfeeding women of all CD4 cell counts at high risk of malaria. The study is
      designed to test the hypothesis that pregnant women receiving a PI-based ART regimen will
      have lower risk of placental malaria compared to pregnant women receiving a non-PI based ART
      regimen. The primary study endpoint of the study is placental malaria. This study also
      enrolls the infants of these women at the time of delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study site will be the Tororo district hospital campus situated in Eastern Uganda, an
      area of high malaria transmission. Using convenience sampling, we will enroll 500
      HIV-infected pregnant women and their infants from the Tororo community. Eligible women
      between 12-28 weeks gestation will be randomized at enrollment to receive either a PI- based
      or an NNRTI-based ART regimen after stratification by gravidity (G1 versus G2+) and
      gestational age (&lt;24 weeks versus ≥ 24 weeks at enrollment).

      Treatment group A will receive Zidovudine 300mg + Lamivudine 150mg + Lopinavir/ritonavir
      200mg/50mg. Treatment group B will receive Zidovudine 300mg + Lamivudine 150mg + Efavirenz
      600mg.

      At enrollment, all study participants will receive a long lasting ITN and, as available, a
      basic care package including a safe water vessel, multivitamins and condoms, as per current
      standard of care for HIV-infected pregnant women in Uganda, if they have not already received
      these interventions from the referral site. Two ITNs will be provided for each mother-infant
      pair. Participants will receive all routine and acute medical care at a designated study
      clinic open 7 days a week from 8 a.m. to 5 p.m. If medical care is needed after hours,
      participants will be instructed to come to Tororo District Hospital premises (where the study
      clinic is located) and request that the study physician on-call be contacted. They will be
      followed up from the time of enrollment during pregnancy and through the cessation of
      breastfeeding; seen monthly for routine assessments and laboratory evaluations. Following
      delivery, the infants of enrolled women will be followed until 6 weeks following the
      cessation of breastfeeding but not beyond 58 weeks of life. Study participants will be
      followed closely for adverse events potentially due to study drugs and for malaria and HIV
      treatment outcomes. During the follow-up period, all patients presenting to the clinic with a
      new episode of fever will undergo standard evaluation (history, physical examination and
      Giemsa-stained blood smear) for the diagnosis of malaria.

      Women will receive the study treatment from the time of study entry and randomization (12-28
      weeks gestation) until 1 week following the cessation of breastfeeding (but no longer than 1
      year + 1 week postpartum). If a subject experiences a toxicity endpoint, ART will be changed
      to provide antiviral activity prior to delivery. Exclusive breastfeeding will be encouraged
      until 24 weeks postpartum which is the standard of care in Uganda. As per updated WHO
      guidelines, women will be encouraged to introduce food at 6 months of life and continue
      breastfeeding until 1 year of life. Women will be counseled to wean over the course of 1
      month and continue antiretrovirals for at least 1 week following weaning. Furthermore, if an
      infant is found to be HIV-infected, Uganda MOH and WHO guidelines recommend the continuation
      of breastfeeding until 2 years of life and daily TS. All women will receive daily oral
      trimethoprim/sulfamethoxazole (TS) per Ugandan MOH guidelines.

      Per Ugandan MOH guidelines, all newborns will receive nevirapine syrup (10mg/ml) starting
      within 12 hours after birth for 6 weeks, daily oral TS from 6 weeks of life until 6 weeks
      following the cessation of breastfeeding, and their mothers will be instructed on ITN use for
      their infants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Malaria Defined as Positive Placental Blood Smear</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of participants with positive placental blood smear for malaria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Malaria Defined as Positive Placental Blood PCR</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of participants with positive placental blood PCR for malaria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placental Malaria Defined as Positive Placental RDT</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy</measure>
    <time_frame>Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Severe Maternal Anemia Defined by Hemoglobin &lt; 8g/dl at Any Point During the Trial in Each Treatment Group</measure>
    <time_frame>Time from randomization until 24 months postpartum or cessation of breastfeeding</time_frame>
    <description>number of evaluated participants with severe maternal anemia defined by hemoglobin &lt; 8g/dl at any point during the trial in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise &gt;20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(&lt;37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days)</measure>
    <time_frame>Time from randomization until 24 months postpartum or cessation of breastfeeding</time_frame>
    <description>Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise &gt;20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(&lt;37wks gestation), neonatal death(death of live-born infant within first 28 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pre-eclampsia Defined by Hypertension &gt; 140/90 on Two Occasions Measured &gt; 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick</measure>
    <time_frame>Time of randomization until 4 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal HIV RNA Suppression of &lt;400 Copies/mL and of &lt;50 Copies/mL</measure>
    <time_frame>At delivery and 24 weeks after the start of the treatment regimen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maternal CD4 Cell Counts and % CD4</measure>
    <time_frame>From ART initiation to delivery and from delivery to the cessation of breastfeeding</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of One or More New Maternal HIV Antiretroviral Resistance Mutations</measure>
    <time_frame>Measured at delivery and 24 weeks postpartum.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Maternal to Child Transmission of HIV, Measured by Infant HIV DNA PCR</measure>
    <time_frame>From delivery to 24 weeks of life or the cessation of breastfeeding if that occurs prior to 24 weeks of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART Levels in Plasma and Hair Samples</measure>
    <time_frame>Women at 30-34 weeks gestation and 12 weeks postpartum; Infants at delivery, 12 weeks and 24 weeks of life.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Grade 3 or 4 Toxicity at Any Point During the Trial in the Two Treatment Groups in Women and in Infants</measure>
    <time_frame>Time from randomization until 24 months postpartum or cessation of breastfeeding</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Malaria Defined Placental Histopathologic Analysis</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of participants with positive placental histopathology slide for malaria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy</measure>
    <time_frame>Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">389</enrollment>
  <condition>Malaria</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ZDV 300mg/3TC 150mg/EFV 600mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>LPV 200mg/r 50mg</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Kaletra</other_name>
    <other_name>Aluvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600mg</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Zidovudine 300 mg</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine 150 mg</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 16 years (if &lt;18 years old, living independently from parents)

          2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV
             RNA, Western blot, or rapid HIV antibody test

          3. Confirmed pregnancy by positive serum or urine pregnancy test or ultrasound

          4. Estimated gestational age between 12 and 28 weeks (based on first day of last
             menstrual period with physical exam confirmation and ultrasound confirmation) at time
             of enrollment

          5. Residency within 30 km of the study site

          6. Willing to provide informed consent

        Exclusion Criteria:

          1. Current or prior use of HAART

          2. Exposure to single-dose NVP (alone or with zidovudine or zidovudine/lamivudine or
             other abbreviated monotherapy or dual therapy for PMTCT) less than 24 months prior to
             enrollment

          3. Prior dose-limited toxicity to TS within 14 days of study enrollment

          4. Receipt of any contraindicated medications within 14 days of study enrollment (See
             Appendix III.)

          5. Active tuberculosis or other WHO Stage 4 diseases

          6. Screening laboratory values:

               1. Hemoglobin: &lt;7.5 g/dL (Note: Women found to have a hemoglobin &lt;7.5 at screening
                  may receive iron and folic acid and/or a blood transfusion at the physician's
                  discretion. If a repeat hemoglobin is ≥7.5 g/dL, the woman may be considered for
                  study inclusion.)

               2. Absolute neutrophil count (ANC): &lt;750/mm3

               3. Platelet count: &lt;50,000/mm3

               4. ALT: &gt;225 U/L (&gt;5.0x ULN)

               5. AST: &gt;225 U/L (&gt;5.0x ULN)

               6. Bilirubin (total): &gt; 2.5x ULN

               7. Creatinine: &gt; 1.8x ULN

          7. Known cardiac conduction abnormalities or structural heart defect

        NOTE: A woman will be excluded from study participation during the current pregnancy if she
        goes into labor, experiences ruptured membranes or develops active tuberculosis or a WHO
        stage 4 condition following study enrollment but prior to study drug initiation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Havlir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Cohan, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses R Kamya, MBChB, MMed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pius Okong, MMed, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ugandan Ministry of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grant Dorsey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tororo District Hospital</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Nsanzabana C, Rosenthal PJ. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother. 2011 Nov;55(11):5073-7. doi: 10.1128/AAC.05130-11. Epub 2011 Aug 29.</citation>
    <PMID>21876053</PMID>
  </reference>
  <reference>
    <citation>Ochong E, Tumwebaze PK, Byaruhanga O, Greenhouse B, Rosenthal PJ. Fitness Consequences of Plasmodium falciparum pfmdr1 Polymorphisms Inferred from Ex Vivo Culture of Ugandan Parasites. Antimicrob Agents Chemother. 2013 Sep;57(9):4245-4251. doi: 10.1128/AAC.00161-13. Epub 2013 Jun 24.</citation>
    <PMID>23796921</PMID>
  </reference>
  <results_reference>
    <citation>Young S, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, Arinaitwe E, Clark T, Ades V, Plenty A, Charlebois E, Ruel T, Kamya M, Havlir D, Cohan D. Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy. PLoS One. 2012;7(8):e41934. doi: 10.1371/journal.pone.0041934. Epub 2012 Aug 7.</citation>
    <PMID>22879899</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohan D, Mwesigwa J, Natureeba P, Aliba Luwedde F, Ades V, Plenty A, Kakuru A, Achan J, Clark T, Osterbauer B, Kamya M, Havlir D. WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity. J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):e101-3. doi: 10.1097/QAI.0b013e31828011ca.</citation>
    <PMID>23924639</PMID>
  </results_reference>
  <results_reference>
    <citation>Ades V, Mwesigwa J, Natureeba P, Clark TD, Plenty A, Charlebois E, Achan J, Kamya MR, Havlir DV, Cohan D, Ruel TD. Neonatal mortality in HIV-exposed infants born to women receiving combination antiretroviral therapy in Rural Uganda. J Trop Pediatr. 2013 Dec;59(6):441-6. doi: 10.1093/tropej/fmt044. Epub 2013 Jun 13.</citation>
    <PMID>23764539</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb;54(2):121-32. doi: 10.1002/jcph.167. Epub 2013 Sep 21.</citation>
    <PMID>24038035</PMID>
  </results_reference>
  <results_reference>
    <citation>Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D; Prevention of Malaria and HIV disease in Tororo (PROMOTE) study. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):578-84. doi: 10.1097/QAI.0b013e31829c48ad.</citation>
    <PMID>24135775</PMID>
  </results_reference>
  <results_reference>
    <citation>Young SL, Plenty AH, Luwedde FA, Natamba BK, Natureeba P, Achan J, Mwesigwa J, Ruel TD, Ades V, Osterbauer B, Clark TD, Dorsey G, Charlebois ED, Kamya M, Havlir DV, Cohan DL. Household food insecurity, maternal nutritional status, and infant feeding practices among HIV-infected Ugandan women receiving combination antiretroviral therapy. Matern Child Health J. 2014 Nov;18(9):2044-53. doi: 10.1007/s10995-014-1450-y.</citation>
    <PMID>24585398</PMID>
  </results_reference>
  <results_reference>
    <citation>Natureeba P, Ades V, Luwedde F, Mwesigwa J, Plenty A, Okong P, Charlebois ED, Clark TD, Nzarubara B, Havlir DV, Achan J, Kamya MR, Cohan D, Dorsey G. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women. J Infect Dis. 2014 Dec 15;210(12):1938-45. doi: 10.1093/infdis/jiu346. Epub 2014 Jun 23.</citation>
    <PMID>24958908</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):128-35. doi: 10.1097/QAI.0000000000000281.</citation>
    <PMID>25072616</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Gandhi M, Clark TD, Nzarubara B, Achan J, Ruel T, Kamya MR, Havlir DV. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015 Jan 14;29(2):183-91. doi: 10.1097/QAD.0000000000000531.</citation>
    <PMID>25426808</PMID>
  </results_reference>
  <results_reference>
    <citation>Young S, Natamba B, Luwedde F, Nyafwono D, Okia B, Osterbauer B, Natureeba P, Johnson L, Michel C, Zheng A, Robine M, Achan J, Charlebois E, Cohan D, Havlir D. &quot;I Have Remained Strong Because of That Food&quot;: Acceptability and Use of Lipid-Based Nutrient Supplements Among Pregnant HIV-Infected Ugandan Women Receiving Combination Antiretroviral Therapy. AIDS Behav. 2015 Aug;19(8):1535-47. doi: 10.1007/s10461-014-0947-0.</citation>
    <PMID>25416075</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, Horng H, Clark TD, Plenty A, Ruel TD, Achan J, Charlebois ED, Kamya MR, Havlir DV, Gandhi M. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015 Apr 24;29(7):825-30. doi: 10.1097/QAD.0000000000000619. Erratum in: AIDS. 2015 Nov;29(17):2369.</citation>
    <PMID>25985404</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Natureeba P, Nyafwono D, Plenty A, Mwesigwa J, Nzarubara B, Clark TD, Ruel TD, Achan J, Charlebois ED, Cohan D, Kamya MR, Havlir DV, Young SL. Brief Report: Food Insufficiency Is Associated With Lack of Sustained Viral Suppression Among HIV-Infected Pregnant and Breastfeeding Ugandan Women. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):310-5. doi: 10.1097/QAI.0000000000000860.</citation>
    <PMID>26397935</PMID>
  </results_reference>
  <results_reference>
    <citation>Marquez C, Chamie G, Achan J, Luetkemeyer AF, Kyohere M, Okiring J, Dorsey G, Kamya MR, Charlebois ED, Havlir DV. Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda. Pediatr Infect Dis J. 2016 May;35(5):524-9. doi: 10.1097/INF.0000000000001062.</citation>
    <PMID>26771662</PMID>
  </results_reference>
  <results_reference>
    <citation>Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 Aug 1;63(3):414-22. doi: 10.1093/cid/ciw291. Epub 2016 May 3.</citation>
    <PMID>27143666</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, Cohan D, Okiring J, Charlebois ED, Kamya MR, Havlir DV. Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda. J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):279-284. doi: 10.1097/QAI.0000000000001228.</citation>
    <PMID>27828878</PMID>
  </results_reference>
  <results_reference>
    <citation>Kakuru A, Natureeba P, Muhindo MK, Clark TD, Havlir DV, Cohan D, Dorsey G, Kamya MR, Ruel T. Malaria burden in a birth cohort of HIV-exposed uninfected Ugandan infants living in a high malaria transmission setting. Malar J. 2016 Oct 18;15(1):500.</citation>
    <PMID>27756308</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <results_first_submitted>January 5, 2015</results_first_submitted>
  <results_first_submitted_qc>October 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2017</results_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Diana Havlir</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Placental Malaria</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Uganda</keyword>
  <keyword>Protease inhibitors</keyword>
  <keyword>Trimethoprim-sulfamethoxazole</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Without Protease Inhibitor</title>
          <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
        </group>
        <group group_id="P2">
          <title>With Protease Inhibitor</title>
          <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Delivered</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Without Protease Inhibitor</title>
          <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
        </group>
        <group group_id="B2">
          <title>With Protease Inhibitor</title>
          <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="194"/>
            <count group_id="B3" value="389"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="5.4"/>
                    <measurement group_id="B2" value="29.0" spread="5.4"/>
                    <measurement group_id="B3" value="29.3" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age, wk</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="4.1"/>
                    <measurement group_id="B2" value="21.2" spread="4.3"/>
                    <measurement group_id="B3" value="21.1" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Preganancies</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bed Net Ownership</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Untreated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes; unknown treatment status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Receiving TMP-SMX prophylaxis at enrollment</title>
          <description>Trimethoprim/sulfamethoxazole (TMP-SMX) is an antibiotic used to treat a variety of bacterial infections. It consists of one part trimethoprim to five parts sulfamethoxazole.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin level, g/dL</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="1.3"/>
                    <measurement group_id="B2" value="11.0" spread="1.2"/>
                    <measurement group_id="B3" value="10.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell count</title>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374" lower_limit="270" upper_limit="485"/>
                    <measurement group_id="B2" value="368" lower_limit="282" upper_limit="506"/>
                    <measurement group_id="B3" value="370.5" lower_limit="274" upper_limit="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV RNA load</title>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" lower_limit="3.5" upper_limit="4.8"/>
                    <measurement group_id="B2" value="4.1" lower_limit="3.3" upper_limit="4.7"/>
                    <measurement group_id="B3" value="4.1" lower_limit="3.4" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO stage HIV disease</title>
          <description>Stage 1=Asymptomatic; Stage 2= Moderate unexplained weight loss, Recurrent respiratory infections, Herpes zoster, Angular cheilitis, Recurrent oral ulceration, Papular pruritic eruptions, Seborrheic dermatitis, Fungal nail infections; Stage 3=Unexplained severe weight loss, Unexplained chronic diarrhea for &gt;1 month, Unexplained persistent fever for &gt;1 month, Persistent oral candidiasis, Oral hairy leukoplakia, Pulmonary tuberculosis, Severe presumed bacterial infections, Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis; Unexplained anemia; Stage 4 =HIV wasting syndrome,etc</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Malaria Defined as Positive Placental Blood Smear</title>
        <description>Number of participants with positive placental blood smear for malaria</description>
        <time_frame>Delivery</time_frame>
        <population>Placental blood smear</population>
        <group_list>
          <group group_id="O1">
            <title>With Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Without Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Malaria Defined as Positive Placental Blood Smear</title>
          <description>Number of participants with positive placental blood smear for malaria</description>
          <population>Placental blood smear</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.76</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.26</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Malaria Defined as Positive Placental Blood PCR</title>
        <description>Number of participants with positive placental blood PCR for malaria</description>
        <time_frame>Delivery</time_frame>
        <population>Placental blood PCR</population>
        <group_list>
          <group group_id="O1">
            <title>With Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Without Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Malaria Defined as Positive Placental Blood PCR</title>
          <description>Number of participants with positive placental blood PCR for malaria</description>
          <population>Placental blood PCR</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.76</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.29</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placental Malaria Defined as Positive Placental RDT</title>
        <description>Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services.</description>
        <time_frame>Delivery</time_frame>
        <population>Some participants did not have a placental specimen taken at delivery in the hospital (e.g. deliveries that occurred at home, missed by staff error, etc)</population>
        <group_list>
          <group group_id="O1">
            <title>With Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Without Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Placental Malaria Defined as Positive Placental RDT</title>
          <description>Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services.</description>
          <population>Some participants did not have a placental specimen taken at delivery in the hospital (e.g. deliveries that occurred at home, missed by staff error, etc)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.45</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.36</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy</title>
        <time_frame>Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Without Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy</title>
          <units>treatments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Severe Maternal Anemia Defined by Hemoglobin &lt; 8g/dl at Any Point During the Trial in Each Treatment Group</title>
        <description>number of evaluated participants with severe maternal anemia defined by hemoglobin &lt; 8g/dl at any point during the trial in each treatment group</description>
        <time_frame>Time from randomization until 24 months postpartum or cessation of breastfeeding</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise &gt;20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(&lt;37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days)</title>
        <description>Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise &gt;20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(&lt;37wks gestation), neonatal death(death of live-born infant within first 28 days)</description>
        <time_frame>Time from randomization until 24 months postpartum or cessation of breastfeeding</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Without Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise &gt;20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(&lt;37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days)</title>
          <description>Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise &gt;20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(&lt;37wks gestation), neonatal death(death of live-born infant within first 28 days)</description>
          <units>% of evaluated participants with outcome</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.21</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.89</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Pre-eclampsia Defined by Hypertension &gt; 140/90 on Two Occasions Measured &gt; 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick</title>
        <time_frame>Time of randomization until 4 weeks postpartum</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal HIV RNA Suppression of &lt;400 Copies/mL and of &lt;50 Copies/mL</title>
        <time_frame>At delivery and 24 weeks after the start of the treatment regimen</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maternal CD4 Cell Counts and % CD4</title>
        <time_frame>From ART initiation to delivery and from delivery to the cessation of breastfeeding</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of One or More New Maternal HIV Antiretroviral Resistance Mutations</title>
        <time_frame>Measured at delivery and 24 weeks postpartum.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Maternal to Child Transmission of HIV, Measured by Infant HIV DNA PCR</title>
        <time_frame>From delivery to 24 weeks of life or the cessation of breastfeeding if that occurs prior to 24 weeks of life</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ART Levels in Plasma and Hair Samples</title>
        <time_frame>Women at 30-34 weeks gestation and 12 weeks postpartum; Infants at delivery, 12 weeks and 24 weeks of life.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Grade 3 or 4 Toxicity at Any Point During the Trial in the Two Treatment Groups in Women and in Infants</title>
        <time_frame>Time from randomization until 24 months postpartum or cessation of breastfeeding</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placental Malaria Defined Placental Histopathologic Analysis</title>
        <description>Number of participants with positive placental histopathology slide for malaria</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Without Protease Inhibitor</title>
            <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Placental Malaria Defined Placental Histopathologic Analysis</title>
          <description>Number of participants with positive placental histopathology slide for malaria</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.06</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.98</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy</title>
        <time_frame>Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy</title>
          <units>treatments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Gestational age between 12 and 28 weeks at time of enrollment up to at least 1 year of follow up after delivery or until study termination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
Lopinavir/ritonavir: LPV 200mg/r 50mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>ZDV 300mg/3TC 150mg/EFV 600mg
Efavirenz: 600mg
Zidovudine: Zidovudine 300 mg
Lamivudine: Lamivudine 150 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep venous Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death, natural causes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Severe anemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Complicated malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abruptio-placenta</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Antepartum hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Intra-uterine fetal death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Preterm contractions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Spontaneous abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="100" subjects_affected="58" subjects_at_risk="194"/>
                <counts group_id="E2" events="130" subjects_affected="62" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Reduced WBC count</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Serum glucose, low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E2" events="24" subjects_affected="11" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="84" subjects_affected="63" subjects_at_risk="194"/>
                <counts group_id="E2" events="64" subjects_affected="46" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dysphagia/odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Fatigue/malaise</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="194"/>
                <counts group_id="E2" events="37" subjects_affected="26" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Oral sores</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pain, general</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Temperature, elevated</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E2" events="33" subjects_affected="24" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Unintentional weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pre-term premature rupture of membranes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Neurosensory alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Urine Protein</sub_title>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="194"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="33" subjects_affected="23" subjects_at_risk="194"/>
                <counts group_id="E2" events="36" subjects_affected="19" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dyspnea/respiratory distress</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="16" subjects_affected="5" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Rash (non-infectious)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A semi-immune population of adults at relatively low risk for malaria; a high rate of TMP-SMX prophylaxis ; A lower than expected incidence of malaria, resulting in the possibility that the study was underpowered</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Diane V Havlir, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>01-415-476-4082 ext 400</phone>
      <email>dhavlir@php.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

